CTRV - ContraVir Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.2401
-0.0299 (-11.07%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.2700
Open0.2800
Bid0.2200 x 1000
Ask0.2500 x 900
Day's Range0.2350 - 0.2800
52 Week Range0.2130 - 2.6000
Volume416,197
Avg. Volume160,398
Market Cap3.988M
Beta (3Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-1.4330
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • Benzingalast month

    The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs Jan. 15) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Avenue Therapeutics ...

  • GlobeNewswirelast month

    ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of liver disease arising from chronic viral infection and non-alcoholic steatohepatitis, announced today that its 2018 Annual Meeting of Stockholders scheduled to be held on January 15, 2019 (the “Annual Meeting”) was adjourned due to a lack of a quorum on the proposals to be approved. The Company intends to set a new record date and will add additional proposals to be voted on at the Annual Meeting. ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted therapies for liver disease arising from chronic hepatitis B, C and D virus (HBV, HVC, HDV) and non-alcoholic steatohepatitis (NASH).

  • GlobeNewswire3 months ago

    ContraVir Pharmaceuticals to Present CRV431 Preclinical Data at the Anti-Fibrotic Drug Development Summit

    EDISON, N.J., Nov. 27, 2018 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs.

  • ContraVir Stock Rose on Clinical Trial Progress Report
    Market Realist7 months ago

    ContraVir Stock Rose on Clinical Trial Progress Report

    On July 23, ContraVir Pharmaceuticals stock closed at $0.95, which represents ~12% growth from its 52-week low of $0.85 on July 20 and 4.7% growth from its close of $0.91 on July 20. ContraVir Pharmaceuticals hit its 52-week high of $6.60 on October 17, 2017. On July 23, ContraVir Pharmaceuticals stock started rising after the company gave an update on its phase 1/2A trial of CRV431.

  • PR Newswire7 months ago

    Live Investor Conference & Webinar: NASDAQ and OTC companies to present live on July 12th

    Company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , July 10, 2018 /PRNewswire/ -- PR Newswire and BetterInvesting (NAIC) today announced the agenda for the ...

  • PR Newswire7 months ago

    ContraVir Pharmaceuticals to Present at Virtual Investor Conference

    Live Webcast Scheduled for July 12, 2018, 10:00 AM ET, followed by Q&A EDISON, N.J. , July 5, 2018 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on ...